Hormone replacement therapy — more accurately called menopausal hormone therapy (MHT) — is one of the most studied medical interventions in women’s health. It is also one of the most misunderstood, surrounded by a mix of outdated fears, genuine nuance, and emerging evidence that has substantially changed clinical guidance over the past decade.
If you have reached menopause (twelve months without a period) or are in the years just after, this article is an honest, evidence-based overview of how MHT affects the body — what it helps, what the risks look like in context, and what questions to bring to your gynaecologist.
This is not a recommendation for or against MHT. Individual medical decisions depend on your complete health history, symptoms, preferences, and circumstances. What this article offers is the information you need to have an informed conversation.
What Happens to the Body After Menopause
After the final menstrual period, oestrogen production by the ovaries drops to a permanently low level. The average age of menopause in India is around 46–47 years — somewhat earlier than the Western average of 51.
Oestrogen is not simply a reproductive hormone. It is active in virtually every tissue in the body: bone, heart, blood vessels, brain, skin, vagina, bladder, and joints. When it falls permanently at menopause, the effects extend far beyond the end of periods and hot flashes.
The long-term consequences of oestrogen withdrawal at menopause include:
- Accelerated bone density loss (leading to osteoporosis)
- Unfavourable shifts in cholesterol and cardiovascular risk markers
- Urogenital changes (vaginal dryness, recurrent urinary tract infections, pelvic floor changes)
- Cognitive changes and increased dementia risk in some populations
- Ongoing vasomotor symptoms (hot flashes, night sweats) in many women for years post-menopause
MHT replaces the oestrogen (and, where needed, progesterone) that the ovaries no longer produce, modifying these downstream effects.
What MHT Does in the Body After Menopause
1. Vasomotor Symptoms: Hot Flashes and Night Sweats
This is where MHT has the clearest, most dramatic benefit. Hot flashes and night sweats are the most common reason women seek treatment after menopause — and MHT is the most effective treatment available.
Studies consistently show that MHT reduces hot flash frequency by 70–90% and significantly reduces severity. For women whose vasomotor symptoms continue for years after menopause — which is common; around 25% of women have significant symptoms beyond 5 years post-menopause — MHT provides sustained relief that lifestyle interventions and non-hormonal options cannot reliably match.
2. Bone Health: Protecting Against Osteoporosis
Bone density declines at an accelerated rate in the years after menopause — most dramatically in the first 5–10 years post-menopause. Oestrogen plays a critical role in maintaining bone density by inhibiting osteoclasts (cells that break down bone).
MHT significantly reduces the rate of bone loss after menopause. Long-term MHT users consistently show higher bone mineral density and substantially lower rates of osteoporotic fractures — hip fractures, spine fractures, and wrist fractures — compared to non-users.
For Indian women, this is particularly relevant. India has a high burden of osteoporosis, worsened by calcium and vitamin D deficiency, and a cultural tendency toward lower sun exposure for women in many communities. The fracture risk from osteoporosis is life-altering: hip fractures in older women carry a 25% one-year mortality rate.
MHT taken during the window of accelerated bone loss (the decade after menopause) can have lasting protective effects on bone architecture, even after it is discontinued.
3. Cardiovascular Health: Timing Is Everything
This is the area with the most nuance — and the most historical confusion.
The case for cardiac benefit: Multiple lines of evidence suggest that MHT started in women under 60, or within 10 years of menopause (the “timing hypothesis” or “window of opportunity”), is associated with reduced cardiovascular events, favourable effects on LDL and HDL cholesterol, reduced arterial stiffness, and lower rates of diabetes onset.
The case for caution: The earlier, widely-publicised Women’s Health Initiative (WHI) study in 2002 found increased cardiovascular risk in MHT users — but this study enrolled women who were on average 63 years old, with 10+ years post-menopause, some of whom had pre-existing cardiovascular disease. Starting MHT in women with established atherosclerosis is different from starting it in recently menopausal women.
Current understanding: Most cardiovascular bodies now support a “healthy user, early start” model — MHT started within the first decade of menopause, in otherwise healthy women, appears to have a neutral to beneficial cardiovascular effect. Starting MHT in women who are many years post-menopause, or who have existing cardiovascular disease, carries a different risk calculation.
Arteries are still oestrogen-responsive. MHT appears cardioprotective or neutral. Bone, brain, and vasomotor benefits are greatest.
Arteries have adapted to low oestrogen. Starting MHT late may not confer the same benefits and could disturb established vascular adaptation in some contexts.
Family history, cardiovascular markers, BMI, smoking history, and other factors modify this picture for every individual.
4. Cognition and Dementia Risk
Oestrogen has neuroprotective functions — it supports neuronal energy metabolism, promotes synaptic plasticity, and has anti-inflammatory effects in brain tissue. Low oestrogen post-menopause is associated with a higher rate of cognitive decline and dementia in epidemiological studies.
The evidence on MHT and cognition is genuinely complex:
Supportive evidence: Women who use MHT around the time of menopause (the same “timing” principle) show lower rates of Alzheimer’s disease in multiple observational studies. Oestrogen appears to support verbal memory, processing speed, and executive function.
Cautionary evidence: The WHI Memory Study (again in older women, average age 65+) found increased dementia risk with combined MHT in this population. This is consistent with the timing hypothesis — starting hormones years after the brain has adapted to oestrogen deficiency may be less beneficial and potentially harmful.
Practical implication: Women who start MHT soon after menopause for symptom management may be receiving neurological benefit as a bonus. Starting MHT specifically to prevent dementia in much older, asymptomatic women is not currently recommended.
5. Urogenital Health: A Consistently Positive Effect
One of the most consistent and unambiguous benefits of oestrogen after menopause is on urogenital tissue. The vaginal wall, urethra, and bladder all depend on oestrogen to maintain their structure, moisture, and function.
After menopause, these tissues atrophy — a condition now called Genitourinary Syndrome of Menopause (GSM). Effects include vaginal dryness, painful intercourse, recurrent urinary tract infections, urinary urgency, and pelvic discomfort.
Local vaginal oestrogen (applied directly to vaginal tissue, not systemic therapy) is extraordinarily effective for GSM. It produces minimal systemic absorption and is considered safe for virtually all women, including those who cannot use systemic MHT. It can be used indefinitely.
Systemic MHT also improves GSM, though local therapy is often preferred or added for this indication specifically.
Affects the whole body. Used for hot flashes, mood, sleep, bone protection, and cardiovascular benefit in the early post-menopausal window. Available as patches, gels, or tablets.
Applied directly to vaginal tissue. Treats dryness, painful intercourse, recurrent UTIs. Minimal systemic absorption. Safe for nearly all women. Does not treat hot flashes.
Women with a uterus must take progestogen alongside oestrogen to protect the uterine lining. Women without a uterus (post-hysterectomy) take oestrogen alone.
Most guidelines support starting systemic MHT within 10 years of menopause for maximum benefit-to-risk ratio. Individual clinical assessment always required.
6. Mood and Psychological Wellbeing
The post-menopausal stabilisation of hormones often brings emotional improvement for many women — the wild fluctuations of perimenopause end, and many women feel significantly better emotionally once hormones settle at their new (lower) baseline.
For women who continue to struggle with low mood, anxiety, or emotional lability post-menopause, MHT can provide benefit — particularly when symptoms appear connected to vasomotor disruption (night sweats disrupting sleep, which then affects mood).
However, MHT is not a treatment for depression. If clinical depression is present, it requires appropriate psychological and/or medical treatment in its own right. MHT can be part of a broader picture but should not be the only support for significant mood disorder.
Understanding the Risks in Context
No medical treatment is without risk. The honest conversation about MHT requires understanding what the risks actually are — in absolute terms, not just relative terms — and for which women they are most relevant.
Breast Cancer: The Central Concern
This is the risk most women have heard about, often in alarming terms. The picture is more nuanced than headlines suggest.
Combined oestrogen-progestogen therapy is associated with a small increased risk of breast cancer. The magnitude of this risk, based on current evidence:
- After 5 years of combined MHT: approximately 1 additional breast cancer per 1,000 women per year (compared to non-users)
- This is comparable in magnitude to the risk associated with being overweight, or with 1–2 glasses of alcohol per night
- The risk appears to reduce after stopping MHT
Oestrogen-only therapy (for women without a uterus) is associated with a smaller, less consistent breast cancer signal, and some studies suggest a reduced risk with long-term oestrogen-only therapy.
The type of progestogen used appears to matter: natural progesterone (bioidentical) appears to carry a lower breast cancer risk than synthetic progestins in observational studies — though clinical trial data is limited.
For a woman whose quality of life is severely impacted by post-menopausal symptoms, the absolute risk from 5 years of MHT is very small. For a woman with BRCA mutations, strong family history, or previous breast cancer, the risk calculation changes significantly — and these women should have an individual conversation with a specialist.
Blood Clots (Venous Thromboembolism)
Oral (tablet) oestrogen increases the risk of DVT (deep vein thrombosis) and pulmonary embolism, particularly in the first year of use, and more so in women who are overweight, older, or have additional risk factors.
Transdermal oestrogen (patches or gels applied to the skin, absorbed directly into the bloodstream) does not appear to carry this increased clot risk. This is now a widely accepted distinction in clinical guidelines, and transdermal delivery is often preferred for this reason.
MHT in the Indian Context
Post-menopausal hormone therapy remains significantly underused in India — surveys suggest that fewer than 5% of eligible Indian women use MHT, compared to 10–15% in the UK and higher rates in parts of Europe.
Contributing factors include:
- Limited awareness among women and, in some cases, among primary care doctors
- Cultural reluctance to seek help for “women’s problems” that are perceived as natural and inevitable
- Historical confusion from the 2002 WHI study that was widely (but inaccurately) extrapolated to all women
- Access: specialist gynaecological consultations are not universally accessible
Indian women starting menopause earlier (average 46–47 years vs. 51 in Western populations) spend more years in the post-menopausal state — which may actually strengthen the case for discussing MHT, given the longer duration of oestrogen deficiency affecting bones, cognition, and cardiovascular health.
Who Should Consider Discussing MHT With Their Doctor?
MHT is worth a dedicated conversation if you:
- Have significant hot flashes or night sweats that are affecting sleep and quality of life
- Are in the first 10 years after menopause (or under 60)
- Have concerns about bone density or have been diagnosed with osteopenia or osteoporosis
- Have significant vaginal dryness, recurrent UTIs, or pain during intercourse
- Experience persistent mood difficulties post-menopause
- Experienced early or premature menopause (before age 45 or 40) — in whom MHT is particularly recommended until at least the average menopausal age
MHT is generally contraindicated (not recommended) in women with:
- Active or recent breast cancer or oestrogen-sensitive cancer
- Recent cardiovascular event (heart attack, stroke)
- Active or untreated blood clots
- Active liver disease
This is not an exhaustive list — your gynaecologist will assess your complete history.
Questions to Ask Your Gynaecologist
Before discussing MHT, it helps to know what you want to ask:
- “Given my symptom profile and when I went through menopause, am I within the window where MHT is considered to have the best benefit-to-risk ratio?”
- “Which route of oestrogen delivery would you recommend for me — patch, gel, or tablet — and why?”
- “Do I need progestogen as well? What form would you recommend?”
- “What would the monitoring look like — how often would you want to review me while I am on MHT?”
- “Are there any personal risk factors from my history that change the picture for me specifically?”
- “What are the options if I want to try MHT but find I do not tolerate it?”
Frequently Asked Questions
Does MHT make you gain weight?
MHT does not cause weight gain in well-conducted trials. The weight gain that many women experience around menopause is related to the metabolic and body composition changes of ageing and declining oestrogen, not to MHT itself. Some women report that MHT actually makes it easier to maintain weight by improving sleep (and therefore energy and activity) and by reducing the stress-cortisol cycle associated with severe hot flashes.
How long can MHT be taken?
Current guidance has moved away from the previous “5 years maximum” rule. The duration depends on why MHT is being used. For vasomotor symptom relief, many women take it until their symptoms subside (often 2–5 years, but sometimes longer). For bone protection or other long-term indications, longer duration may be appropriate, under periodic review. Your gynaecologist should review your MHT every year.
If I stop MHT, will all my symptoms return?
Hot flashes often return temporarily when MHT is stopped, particularly if stopped abruptly. Gradual dose reduction is usually recommended. For most women, vasomotor symptoms will eventually resolve on their own over time — the question is at what point that occurs.
Is there a difference between “HRT” and “MHT”?
They refer to the same thing. “Menopausal hormone therapy (MHT)” is the current preferred term because it is more accurate — the therapy replaces hormones lost at menopause rather than replacing all hormones. “HRT” (hormone replacement therapy) is still widely used, especially in India.
Can I use MHT if I still occasionally get periods (late perimenopause)?
Yes — there are MHT formulations designed for perimenopausal women who are not yet fully post-menopausal. These typically include a cyclic progestogen component. This is distinct from post-menopausal MHT. Discuss the timing and formulation with your gynaecologist.
What about “bioidentical” hormones sold privately?
Compounded or custom-made “bioidentical” hormone preparations are widely marketed but not regulated as rigorously as standard pharmaceutical products in India. The hormones in them (oestradiol, progesterone, testosterone) are the same molecules as in regulated MHT — “bioidentical” refers to the molecular structure, not the preparation method. Standard pharmaceutical MHT already includes bioidentical oestradiol and micronised progesterone in regulated, tested doses. Custom compounding bypasses quality controls that exist for good reason. Discuss this specifically with your gynaecologist if you are interested.
